CuraSen Therapeutics, Inc.
PrivateLast Round
Series B
Aug 20, 2024
Est. Valuation
$123.5M
Total Funding Raised
$84.11M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
CuraSen Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small molecule drugs to treat a broad range of psychiatric and neurodegenerative diseases, including Parkinson's and Alzheimer's disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CuraSen Therapeutics, Inc. Comparables
Compare CuraSen Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Myrobalan Therapeutics | 81% | |
| Athira Pharma | 77% | |
| Gain Therapeutics Inc | 73% |
CuraSen Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 20, 2024 | ||||
| Grant | Oct 9, 2023 | ||||
| Series A Extension | Nov 5, 2021 | ||||
| Series A | Oct 17, 2018 |
CuraSen Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series A |
| New Leaf Venture Partners | Series A |
| A. M. Pappas & Associates | Series A Extension, Series A |
| Tekla Capital Management | Series A |
| Chiesi Ventures | Series A Extension |
| Johnson & Johnson Innovation - JJDC, Inc. | Series A |
| ICG Infra | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 55% MoM, from 1.7K to 2.7K.
- Jun 21, 2026
Monthly visitors increased 115% MoM.
CuraSen Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about CuraSen Therapeutics, Inc.'s valuation, stock price, and market status.
Is CuraSen Therapeutics, Inc. a public or private company?
CuraSen Therapeutics, Inc. is a private company.
What is the current stock price of CuraSen Therapeutics, Inc.?
CuraSen Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks CuraSen Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CuraSen Therapeutics, Inc. worth (valuation)?
CuraSen Therapeutics, Inc.'s valuation is estimated at $123.5M based on funding round data.
Can I buy CuraSen Therapeutics, Inc. stock?
CuraSen Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CuraSen Therapeutics, Inc.'s last funding round?
CuraSen Therapeutics, Inc.'s most recent funding round was Series B on August 20, 2024.
Who are the main investors in CuraSen Therapeutics, Inc.?
Key investors in CuraSen Therapeutics, Inc. include New Leaf Venture Partners.
Will CuraSen Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for CuraSen Therapeutics, Inc..
How can I track CuraSen Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in CuraSen Therapeutics, Inc.'s shares on secondary markets.